Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 316.78% | 160.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 102.82% | 53.19% | |||
| Operating Income | -102.82% | -53.19% | |||
| Income Before Tax | -110.53% | -80.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -110.53% | -80.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -110.53% | -80.11% | |||
| EBIT | -102.82% | -53.19% | |||
| EBITDA | -113.79% | -61.18% | |||
| EPS Basic | -110.50% | -79.84% | |||
| Normalized Basic EPS | -92.12% | -53.84% | |||
| EPS Diluted | -110.50% | -79.84% | |||
| Normalized Diluted EPS | -92.12% | -53.84% | |||
| Average Basic Shares Outstanding | 0.07% | 0.14% | |||
| Average Diluted Shares Outstanding | 0.07% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||